There will be a total of 9 visits and a 1 and 3 day post dosing telephone contact with the patient to evaluate for any new complaints. Following screening visits(V1 and V1A) and study drug administration at week 0, eligible participants will be evaluated for safety post dosing with study drug at weeks 1, 2, 4, 8, 12, and 24.